Generics - Antibiotics and Infectious diseases, Oncology, Kilitch Drugs

Actavis pays Valeant $55M for drug rights; Incyte gets $25M milestone

02-05-2013

US generics major Actavis (NYSE: ACT), reportedly the subject of a stalled takeover bid from Canada's…

ActavisAntibiotics and Infectious diseasesFinancialGenericsINC280IncyteLicensingMetronidazole LotionNovartisOncologyPharmaceuticalResearchValeant Pharmaceuticals

India's Macleods Pharma to invest $25 million in production in Russia; Ferring to start manufacturing

14-12-2012

Indian drugmaker Macleods plans to invest up to 700 million roubles (around $25 million) in the construction…

Antibiotics and Infectious diseasesEuropeFerring PharmaceuticalsGenericsIzvarino PharmaMacleods PharmaceuticalsOncologyPharmaceuticalProduction

ViroPharma stock plunges on bad news for Vancocin; Sanofi patents invalidated

11-04-2012

ViroPharma I (Nasdaq: VPHM) saw its shares plunge 19% to $23.25 yesterday after it announced that the…

Antibiotics and Infectious diseasesApotexGenericsHospiraLegalNorth AmericaOncologyPatentsPharmaceuticalRegulationSanofiTaxotereVancocinViroPharmaWatson Pharmaceuticals

Generic launches of irinotecan, Primaxin and Merrem

08-02-2012

Japan’s ASKA Pharmaceuticals has announced the launch of irinotecan, the active ingredient of Campto…

ActavisAntibiotics and Infectious diseasesAPP PharmaceuticalsASKA PharmaceuticalsFresenius KabiGenericsirinotecanMarkets & MarketingMerrem I.V.Oncology

Parexel

Parexel

Back to top